DNA epigenetic signature predictive of benefit from neoadjuvant chemotherapy in oesophageal adenocarcinoma: results from the MRC OE02 trial.

MLA

Sundar, Raghav, et al. “DNA Epigenetic Signature Predictive of Benefit from Neoadjuvant Chemotherapy in Oesophageal Adenocarcinoma: Results from the MRC OE02 Trial.” European Journal of Cancer (Oxford, England : 1990), vol. 123, Dec. 2019, pp. 48–57. EBSCOhost, https://doi.org/10.1016/j.ejca.2019.09.016.

APA

Sundar, R., Ng, A., Zouridis, H., Padmanabhan, N., Sheng, T., Zhang, S., Lee, M. H., Ooi, W. F., Qamra, A., Inam, I., Hewitt, L. C., So, J. B.-Y., Koh, V., Nankivell, M. G., Langley, R. E., Allum, W. H., Cunningham, D., Rozen, S. G., Yong, W. P., … Tan, P. (2019). DNA epigenetic signature predictive of benefit from neoadjuvant chemotherapy in oesophageal adenocarcinoma: results from the MRC OE02 trial. European Journal of Cancer (Oxford, England : 1990), 123, 48–57. https://doi.org/10.1016/j.ejca.2019.09.016

Chicago

Sundar, Raghav, Alvin Ng, Hermioni Zouridis, Nisha Padmanabhan, Taotao Sheng, Shenli Zhang, Ming Hui Lee, et al. 2019. “DNA Epigenetic Signature Predictive of Benefit from Neoadjuvant Chemotherapy in Oesophageal Adenocarcinoma: Results from the MRC OE02 Trial.” European Journal of Cancer (Oxford, England : 1990) 123 (December): 48–57. doi:10.1016/j.ejca.2019.09.016.